(MRKR) Marker Therapeutics, Inc. Business Model Canvas Research

Marker Therapeutics, Inc. depends on oncology investigators, especially key opinion leaders and principal investigators, to shape trial design, run studies, and keep enrollment disciplined in hematological malignancies and solid tumors. Their academic credibility matters because clinical-stage biotech value is often tied to early data quality, and trial success can hinge on site-level execution, protocol adherence, and expert readouts.

• Guide protocol design and amendments
• Improve trial execution and enrollment
• Support credibility in early-stage data
• Help with blood and solid tumor studies

Marker Therapeutics, Inc. depends on capital providers because it is still a public clinical-stage company with no product revenue. Equity funding helps pay for R and D, clinical trials, and overhead across a long path before commercialization, so access to new cash is a key partnership for survival and growth.

• Equity funds trials and R and D.
• No launch revenue yet.
• Long development cycle needs outside capital.

Marker Therapeutics, Inc. needs strong process development and CMC (chemistry, manufacturing, and controls) to keep cell therapies reproducible, with tight QC and release testing before each clinical lot ships. This is critical for both autologous and donor-derived products, where manufacturing consistency drives clinical supply and trial readiness.

• Builds repeatable cell-therapy lots

• Runs QC and release testing

• Supports autologous and donor-derived supply

Marker Therapeutics, Inc. relies on regulatory strategy to keep its clinical-stage immuno-oncology programs aligned with FDA expectations, from protocol review to safety reporting and trial amendments. This work is key to keeping U.S. development moving, especially as the company advances human studies that must stay compliant at every step.

• Aligns trial plans with FDA rules
• Manages safety reports and amendments
• Supports U.S. clinical development

Marker Therapeutics, Inc.'s clinical data package is a core resource because ongoing and historical trial readouts shape dose selection, expansion cohorts, and program ranking. It also strengthens partnering and fundraising by showing response, safety, and durability trends that investors and pharma partners can underwrite.

• Guides dose and expansion choices
• Ranks programs by clinical signal
• Supports partnering talks
• Improves fundraising credibility

Marker Therapeutics, Inc. is based in Houston, Texas, which ties its corporate and scientific work to the Texas Medical Center, a 2.1-square-mile biomedical cluster that serves 10 million patient visits a year. That hub gives the Company direct access to hospitals, researchers, and trial sites, helping anchor operations where cell therapy talent and partners are concentrated.

• Houston HQ links to the Texas Medical Center.
• Access to major biomedical partners.
• Supports corporate and scientific operations.

Marker Therapeutics, Inc. spans lymphoma, AML, ALL, and solid tumors, plus breast and ovarian cancer vaccine programs. This breadth widens the addressable oncology market and reduces dependence on any single tumor type, with several programs aimed at high-unmet-need cancers.

• Targets 6+ oncology programs
• Covers blood and solid tumors
• Includes vaccine assets
• Expands market reach

TPIV200 gives Marker Therapeutics, Inc. a Phase 2 vaccine asset already tested in breast and ovarian cancers, so the value proposition is less binary than early T cell programs: it adds a nearer-term immunotherapy path with clinical de-risking and broader pipeline balance. It can support later-stage optionality while the earlier programs mature.

• Phase 2 asset: TPIV200
• Indications: breast, ovarian cancer
• Adds later-stage pipeline depth
• Complements early T cell programs

Marker Therapeutics, Inc. relies on regular scientific exchange with oncology experts and research stakeholders to build trust in a complex, pre-revenue cell therapy market. Data readouts, abstracts, and peer-reviewed papers keep the dialogue current and help turn early clinical signals into credible evidence.

• Ongoing expert dialogue supports trial adoption and visibility.
• Abstracts and publications translate data into trust.
• Scientific credibility is the main customer bond here.

For a company like Marker Therapeutics, this matters because each new dataset can shape clinician interest, investor confidence, and future study design.

Marker Therapeutics, Inc. depends on partner management for business development and licensing, where data sharing, diligence, and deal talks shape future non-commercial value. This matters because biotech partnering can convert research assets into cash, milestones, and validation without sales force spend.

• Drives data sharing and diligence
• Supports licensing and deal talks
• Can create future milestone value

Peer-reviewed publications are a key channel for Marker Therapeutics, Inc. because they turn trial readouts and mechanism-of-action data into third-party validated science, which is critical for a clinical-stage biotech with no product revenue and a 2025 market cap still driven mainly by pipeline trust.

• Builds scientific credibility
• Explains trial and MOA data
• Helps investors value the pipeline

Corporate website is Marker Therapeutics, Inc. main direct channel for company news, pipeline updates, and investor materials. For a small public biotechnology company, an always-on site helps reach patients, investors, and partners at low cost and keeps one source of truth for SEC filings, presentations, and trial updates.

• Direct access to pipeline and investor updates
• Supports patients, investors, and partners
• Critical low-cost channel for a small public biotech

Breast and ovarian cancer patients are a clear vaccine-oriented segment for Marker Therapeutics, Inc., since TPIV100, TPIV110, and TPIV200 are designed for these tumors and fit its peptide-based immunotherapy mix with the T cell pipeline. Globally, breast cancer had about 2.3 million new cases in 2022, and ovarian cancer about 324,000, so the addressable need is large and well defined.

• TPIV programs target breast and ovarian tumors
• Fits peptide-based immunotherapy strategy
• Large need: 2.3M and 324K cases in 2022

Oncology hospitals and investigators are the practical buyers and users of Marker Therapeutics, Inc.'s platform: they run the trials, enroll patients, and generate the clinical evidence needed for later commercialization. In oncology, that evidence base is built site by site, often across dozens of patients per study, so adoption by major cancer centers and physicians is the key gatekeeper to any future market launch.

• Cancer centers run the trials

• Physicians generate clinical evidence

• Adoption drives later commercialization

Regulatory filings, quality systems, and compliance operations create steady, non-optional spend for Marker Therapeutics, Inc., because clinical-stage biotech must keep FDA-facing work, GxP controls, and lot oversight running even before revenue. These costs often sit inside R&D and G&A, which for small biotech can run in the multi-million-dollar range each year.

• Mandatory for clinical development
• Drives product consistency
• Adds fixed compliance overhead

Marker Therapeutics, Inc. carries public-company overhead in general and administrative expense: executive pay, finance, legal, investor relations, and Houston headquarters operations. In fiscal 2025, that base cost stayed in the single-digit millions to low-teen millions range, and it matters because every dollar spent here cuts into cash available for clinical work.

• Exec, finance, legal, and IR costs
• Houston HQ overhead
• Public-company base spending

Marker Therapeutics had 0 product revenue in 2025, so sponsored research and collaboration agreements can be a key non-product cash source for early-stage oncology work. These deals help fund specific development tasks before clinical assets can generate commercial sales.

• Non-product funding supports early research.
• Useful before product revenue starts.

Future product sales could become a revenue stream only if Marker Therapeutics gets approval for a cell therapy or peptide vaccine. For now, it remains clinical-stage, so 2025 revenue is still tied to development work, not commercial product sales.

• Approval first, sales later
• Cell therapies or peptide vaccines
• No approved products yet